110 related articles for article (PubMed ID: 9762901)
1. Inhibition of glycosaminoglycan modification of perlecan domain I by site-directed mutagenesis changes protease sensitivity and laminin-1 binding activity.
Sasaki T; Costell M; Mann K; Timpl R
FEBS Lett; 1998 Sep; 435(2-3):169-72. PubMed ID: 9762901
[TBL] [Abstract][Full Text] [Related]
2. Localization of glycosaminoglycan substitution sites on domain V of mouse perlecan.
Tapanadechopone P; Hassell JR; Rigatti B; Couchman JR
Biochem Biophys Res Commun; 1999 Nov; 265(3):680-90. PubMed ID: 10600481
[TBL] [Abstract][Full Text] [Related]
3. Structural basis of glycosaminoglycan modification and of heterotypic interactions of perlecan domain V.
Friedrich MV; Göhring W; Mörgelin M; Brancaccio A; David G; Timpl R
J Mol Biol; 1999 Nov; 294(1):259-70. PubMed ID: 10556044
[TBL] [Abstract][Full Text] [Related]
4. Activin A binds to perlecan through its pro-region that has heparin/heparan sulfate binding activity.
Li S; Shimono C; Norioka N; Nakano I; Okubo T; Yagi Y; Hayashi M; Sato Y; Fujisaki H; Hattori S; Sugiura N; Kimata K; Sekiguchi K
J Biol Chem; 2010 Nov; 285(47):36645-55. PubMed ID: 20843788
[TBL] [Abstract][Full Text] [Related]
5. Binding of the G domains of laminin alpha1 and alpha2 chains and perlecan to heparin, sulfatides, alpha-dystroglycan and several extracellular matrix proteins.
Talts JF; Andac Z; Göhring W; Brancaccio A; Timpl R
EMBO J; 1999 Feb; 18(4):863-70. PubMed ID: 10022829
[TBL] [Abstract][Full Text] [Related]
6. The C-terminal domain V of perlecan promotes beta1 integrin-mediated cell adhesion, binds heparin, nidogen and fibulin-2 and can be modified by glycosaminoglycans.
Brown JC; Sasaki T; Göhring W; Yamada Y; Timpl R
Eur J Biochem; 1997 Nov; 250(1):39-46. PubMed ID: 9431988
[TBL] [Abstract][Full Text] [Related]
7. Endothelial cells interact with the core protein of basement membrane perlecan through beta 1 and beta 3 integrins: an adhesion modulated by glycosaminoglycan.
Hayashi K; Madri JA; Yurchenco PD
J Cell Biol; 1992 Nov; 119(4):945-59. PubMed ID: 1385448
[TBL] [Abstract][Full Text] [Related]
8. Identification of sites in domain I of perlecan that regulate heparan sulfate synthesis.
Dolan M; Horchar T; Rigatti B; Hassell JR
J Biol Chem; 1997 Feb; 272(7):4316-22. PubMed ID: 9020150
[TBL] [Abstract][Full Text] [Related]
9. Formation of heparan sulfate or chondroitin/dermatan sulfate on recombinant domain I of mouse perlecan expressed in Chinese hamster ovary cells.
Kokenyesi R; Silbert JE
Biochem Biophys Res Commun; 1995 Jun; 211(1):262-7. PubMed ID: 7779094
[TBL] [Abstract][Full Text] [Related]
10. Perlecan gene expression precedes laminin gene expression during differentiation of F9 embryonal carcinoma cells.
Chakravarti S; Hassell JR; Phillips SL
Dev Dyn; 1993 Jun; 197(2):107-14. PubMed ID: 8219353
[TBL] [Abstract][Full Text] [Related]
11. The N-terminal globular domain of the laminin alpha1 chain binds to alpha1beta1 and alpha2beta1 integrins and to the heparan sulfate-containing domains of perlecan.
Ettner N; Göhring W; Sasaki T; Mann K; Timpl R
FEBS Lett; 1998 Jul; 430(3):217-21. PubMed ID: 9688542
[TBL] [Abstract][Full Text] [Related]
12. Site-directed mutagenesis of a putative heparin binding domain of avian lipoprotein lipase.
Berryman DE; Bensadoun A
J Biol Chem; 1993 Feb; 268(5):3272-6. PubMed ID: 8429005
[TBL] [Abstract][Full Text] [Related]
13. Structural and cell-adhesive properties of three recombinant fragments derived from perlecan domain III.
Schulze B; Sasaki T; Costell M; Mann K; Timpl R
Matrix Biol; 1996 Nov; 15(5):349-57. PubMed ID: 8981331
[TBL] [Abstract][Full Text] [Related]
14. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor.
Murdoch AD; Dodge GR; Cohen I; Tuan RS; Iozzo RV
J Biol Chem; 1992 Apr; 267(12):8544-57. PubMed ID: 1569102
[TBL] [Abstract][Full Text] [Related]
15. The crystal structure of a laminin G-like module reveals the molecular basis of alpha-dystroglycan binding to laminins, perlecan, and agrin.
Hohenester E; Tisi D; Talts JF; Timpl R
Mol Cell; 1999 Nov; 4(5):783-92. PubMed ID: 10619025
[TBL] [Abstract][Full Text] [Related]
16. Expression of human perlecan domain I as a recombinant heparan sulfate proteoglycan with 20-kDa glycosaminoglycan chains.
Graham LD; Whitelock JM; Underwood PA
Biochem Biophys Res Commun; 1999 Mar; 256(3):542-8. PubMed ID: 10080934
[TBL] [Abstract][Full Text] [Related]
17. Recombinant domain IV of perlecan binds to nidogens, laminin-nidogen complex, fibronectin, fibulin-2 and heparin.
Hopf M; Göhring W; Kohfeldt E; Yamada Y; Timpl R
Eur J Biochem; 1999 Feb; 259(3):917-25. PubMed ID: 10092882
[TBL] [Abstract][Full Text] [Related]
18. Interactions of neural glycosaminoglycans and proteoglycans with protein ligands: assessment of selectivity, heterogeneity and the participation of core proteins in binding.
Herndon ME; Stipp CS; Lander AD
Glycobiology; 1999 Feb; 9(2):143-55. PubMed ID: 9949192
[TBL] [Abstract][Full Text] [Related]
19. Perlecan domain V of Drosophila melanogaster. Sequence, recombinant analysis and tissue expression.
Friedrich MV; Schneider M; Timpl R; Baumgartner S
Eur J Biochem; 2000 Jun; 267(11):3149-59. PubMed ID: 10824099
[TBL] [Abstract][Full Text] [Related]
20. The neural cell adhesion molecule (NCAM) heparin binding domain binds to cell surface heparan sulfate proteoglycans.
Kallapur SG; Akeson RA
J Neurosci Res; 1992 Dec; 33(4):538-48. PubMed ID: 1484387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
